Review

B cell abnormalities in systemic lupus erythematosus

Amrie C Grammer and Peter E Lipsky

Autoimmunity Branch of the Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

Correspondence to: Amrie C Grammer (e-mail: grammera@mail.nih.gov)

Received: 9 Sep 2003   Accepted: 22 Oct 2003   Published: 2 Dec 2003

Arthritis Res Ther 2003, 5(Suppl 4):S22-S27 (DOI 10.1186/ar1009)
© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by the differentiation of short- and long-lived immunoglobulin secreting plasma cells that secrete pathogenic autoantibodies. Ectopic germinal centers and plasma cells secreting autoantibodies have been observed in lupus nephritis kidneys. Candidate genetic susceptibility loci for SLE include genes that affect differentiation and survival of plasma cells, such as those that influence activation, proliferation, cytokine and chemokine secretion/responsiveness, and apoptosis of the T and B cells that are involved in humoral immunity generated in germinal centers, as well as genes that are involved in presentation and clearance of apoptotic material and autoantigens by antigen presenting cells and other phagocytes. Emerging data have demonstrated that B lymphocytes are active participants in humoral immune responses that lead to T-dependent and T-independent differentiation of immunoglobulin-secreting plasma cells by homotypic CD154–CD40 interactions as well as continued stimulation by B cell activating factor through B cell maturation antigen, B cell activating factor receptor and transmembrane activator.

Keywords: B cells, germinal centers, immunoglobulin-secreting cells, plasma cells, systemic lupus erythematosus

Introduction

Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease. It is a chronic, multisystem disease that is characterized by abnormal B cell activation and differentiation to memory or plasma effector cells. Abnormal memory effector cells in SLE have specificity for autoantigen with surface immunoglobulin that is usually of high avidity because of somatic hypermutation of immunoglobulin variable regions and possible switching to the IgG isotype. Abnormal plasma effector cells in SLE secrete pathogenic autoantibodies including those that are specific for double stranded (ds)DNA and are involved in glomerulonephritis, those that are specific for phospholipid-β2 glycoprotein I or cardiolipin and are involved in thrombosis, those directed to Ro SSA or La SSB and are involved in the etiology of congenital heart block, and those specific for Sm/RNP whose mechanism of action is unclear [1–3].

The precise cause of SLE is unclear, but the initial presentation of disease appears to depend on a multitude of genetic susceptibility and environmental factors that initiate and/or contribute to pathogenic autoimmunity. Candidate initiating factors include female sex hormones, ultraviolet light from sun exposure, cigarette smoking, and infections with bacteria and/or viruses that polyclonally activate B cells. More frequent or aggressive disease is associated with African-American or African-Caribbean origin, but SLE also emerges in Asian and Caucasian populations. Genetic susceptibility loci include genes that affect differentiation and survival of immunoglobulin secreting cells (ISCs), such as those that influence activation, proliferation, cytokine and chemokine secretion/responsiveness, and apoptosis of the T and B cells that are involved in humoral immunity generated in germinal centers (GCs), as well as genes that are involved in presentation and clearance of apoptotic material and...
autoantigens by antigen presenting cells and other phagocytes [4].

**The role of B cells in systemic lupus erythematosus**

Emerging data have demonstrated that B lymphocytes are active participants in humoral immune responses that lead to differentiation of ISCs. For example, activated B cells in secondary lymphoid tissues and in the blood of patients with active SLE express CD154/TNFSF5/CD40 ligand, and homotypic CD154–CD40/TNFRSF5 interactions between B cells from these sources are crucial for differentiation to ISCs [5–8]. Moreover, differentiation of ISCs is affected by continued stimulation by B cell activating factor (BAFF/BlyS/TNFSF13B) through two of its receptors – B cell maturation antigen (BCMA) and BAFF receptor (BAFF-R) – in a T dependent (TD) manner [9], and through its third receptor – transmembrane activator and CAML interactor (TACI) – in a T independent (TI) manner [10–13]. Of note, BAFF is located in an SLE susceptibility locus (13q32-34) [14–17] and has been found to be elevated in the serum of patients with active SLE [18,19].

Simultaneous emergence of the idea that B cells play a role in autoregulating humoral immune responses, and data suggesting that B cells from active SLE patients and lupus prone mice have an intrinsic tendency to overreact to immunologic stimulation during antigenic challenge have set the stage for novel hypotheses regarding therapeutic approaches to interfere with the emergence and progression of SLE. The profound B cell abnormalities observed in SLE patients may either reflect the impact of multiple genetic factors that affect intrinsic B cell function and/or they may be secondary to other primary immunologic abnormalities [1]. For example, abnormalities during B cell differentiation in secondary lymphoid tissues may permit the generation and survival of ISCs that secrete pathogenic autoantibodies. Alternatively, an intrinsic tendency to respond excessively to immunologic stimulation may provide the drive for the emergence of pathogenic ISCs, even though B cell maturation, somatic hypermutation of immunoglobulin, and subsequent selection are not mechanistically abnormal. Because the mature B cell repertoire has tremendous cellular turnover every day, even minor abnormalities may lead to active SLE over time [20]. Importantly, the emergence of active SLE does not usually occur until the second or third decade of life. Development of SLE during childhood may reflect a greater total load of genetic and environmental influences.

**Immunoglobulin secreting cells**

ISCs are defined by very high expression of CD38 and the presence of intracellular immunoglobulin [21,22]. In addition, all ISCs have a high ratio of secreted to membrane forms of immunoglobulin heavy chain mRNA, a high cytoplasmic to nuclear ratio with prominent endoplasmic reticulum, expanded Golgi apparatus and secretory vacuoles, and expression of J chain – a molecule that is involved in polymerization of IgM and IgA. In normal individuals the ISC B cell pool secretes immunoglobulin that protects the host from infection. In SLE patients the ISC B cell pool secretes pathogenic autoantibodies that contribute to disease activity.

There are two subsets of ISCs, long-lived plasma cells and short-lived plasmablasts/plasmacytes, which are generated in normal immune responses and that are found to secrete autoantibodies in SLE [23]. Long-lived plasma cells are generated during TD humoral immune responses, arise in GC reactions, and home to the bone marrow where they produce antibodies for protracted periods of time in the absence of T cells and antigenic stimulation. In contrast, plasmablasts/plasmacytes often arise during TI humoral responses, and under normal circumstances they remain in the lymphoid tissue in which they are generated.

Long-lived plasma cells are generated in response to TD stimulation in GCs and home to the bone marrow, where they survive for long periods of time. They secrete antibodies constitutively, which accounts for the majority of serum immunoglobulin and long-lived immunity to many antigens [23]. The lifespan of long-lived plasma cells has been observed to be months to years. In addition, long-lived plasma cells are nondividing cells in the G0/G1 phase of the cell cycle that have downregulated many mature B cell markers including CD40, CD19, surface immunoglobulin, and CD20 [23]. As a result, they are not responsive to either T cells or antigens. Moreover, they are not affected by therapy with rituximab, which deletes CD20+ B cells. Moreover, when cultured in vitro, long-lived plasma cells have the capacity to secrete immunoglobulin in the presence of antiproliferative agents such as hydroxyurea [24–26]. Finally, long-lived plasma cells largely derive from conventional (B2) B cells, are the products of TD GC reactions, and their immunoglobulin genes bear the impact of somatic hypermutation and selection [22]. Of interest, the ISCs that secrete immunoglobulin specific for cardiolipin, antinuclear antibodies, Ro, La, and Sm that are found in SLE patients are likely to be long-lived plasma cells because treatment with antiproliferative reagents has minimal effect on plasma levels of these autoantibodies [27,28]. In addition, autologous stem cell transplantation may not eliminate long-lived plasma cells producing these particular autoantibodies because plasma titers are not diminished [29].
Therefore, the majority of IgM plasmablasts may be derived from the B1 subset in BAFF-R deficient mice. In humans, BAFF stimulation of splenic CD38−CD27+ memory B cells that express very high levels of BAFF-R, but little or no BCMA or TACI, increases survival of this memory B cell population and induces differentiation of plasmablasts and plasma cells [11]. Whereas BAFF increased the survival and amount of immunoglobulin secreted from human plasmablasts, BAFF has no direct effect on immunoglobulin secretion from fully differentiated nondividing human CD20− plasma cells.

Mice genetically deficient for an alternative BAFF receptor, TACI (TNFRSF13B), are not able to generate plasmablasts in response to TI antigens [37,38]. Moreover, mice transgenic for APRIL/TALL2/TNFSF13, the TACI and BCMA ligand, had an exaggerated serum IgM response to TI antigens [39]. In mice transgenic for phosphorylcholine specific immunoglobulin, soluble BAFF derived from *Streptococcus pneumoniae* loaded splenic dendritic cells or peritoneal macrophages, respectively, drove antigen induced survival and IgM plasmablast differentiation from marginal zone or B1 B cells in a TACI dependent manner. Forced expression of bcl-2 in this system rescued antigen induced B cell apoptosis that resulted with the TACI Ig fusion protein [12]. Of note, BAFF stimulation of B cells has been shown to induce expression of antiapoptotic molecules in the bcl-2 family. Using dense human tonsillar B cells containing the subepithelial marginal zone-like CD5− memory subset, soluble BAFF derived from peripheral blood derived dendritic cells or macrophages co-stimulated B cell proliferation induced by anti-IgM, but not by recombinant CD154/CD40 ligand, in a manner that did not require APRIL [13].

The role of CD154−CD40 interactions in generation of immunoglobulin secreting cells

Examination of children or mice with defective expression of CD40 or CD154 [5,40] has demonstrated that CD154−CD40 interactions are essential for formation of GCs and the differentiation of memory and plasma cell effector populations. GCs have been shown to be initiated when CD154 expressing T cells engage CD40 expressing B cells in the extrafollicular regions of secondary lymphoid tissues, thereby inducing them to express CD154 [7] and to proliferate rapidly to form the dark zone of GC reactions. Homotypic B cell interactions involving CD154 and CD40 have been shown to be essential for differentiation of GC B cells to memory B cells, and for the formation of secondary GC structures that allow reactivated memory B cells to differentiate into plasma cells secreting high affinity antibodies [7]. The presence of blocking anti-CD154 antibody inhibits the initiation of GC reactions and causes ongoing GC reactions to disassemble in immunized [41] and lupus prone mice [42]. Moreover, the presence of GC and GC derived memory and immunoglobulin secreting plasma effector populations in the periphery of
patients with active SLE is greatly diminished following treatment with blocking anti-CD154 antibody (BG9588, 5c8) [8,43,44]. Importantly, CD154 has been found to be hyper-expressed on lymphocytes in secondary lymphoid tissues from lupus prone mice and from active SLE patients [45,46], and mice transgenic for CD154 on all cells [47], T cells alone [48], or B cells alone [49] spontaneously developed GC reactions that resulted in anti-dsDNA secreting plasmablasts.

**Ectopic germinal centers**

Normally, in non-autoimmune situations, GC reactions and GC generated effector cells are observed in secondary lymphoid tissues (lymph nodes, spleen, and mucosal tissues such as tonsil and Peyer’s patches). Recent studies have observed that inflammation occurring in many autoimmune/inflammatory conditions drives GC/follicle formation in many ectopic sites, including the kidney in lupus nephritis [50–52]. Ectopic GCs/follicle development in autoimmune tissues with a large amount of autoantigen, such as dsDNA in lupus nephritis kidneys, may create an environment in which autoreactive B cells undergo somatic hypermutation, IgH class switching, and positive selection mediated by the autoantigen to the functional memory and plasma cell effector pools.

**Germinal centers in systemic lupus erythematosus**

The dysregulation of mechanisms controlling normal or ectopic TD GC reactions to exogenous or endogenous antigens may contribute to the emergence of SLE. Normally, immature polyreactive and mature B cells with specificity for endogenous autoantigens are excluded from follicular GC reactions that generate memory and immunoglobulin secreting plasma effector cells. The elements that may contribute to these events in humans have not been fully characterized, but recruitment of autoreactive B cells into TD GC reactions that generate memory and plasma cell effector cells.

In this regard, exposure of anergic, nonresponsive, autoreactive B cells to exogenous CD154 resulted in proliferation, antigen presentation, and immunoglobulin secretion at levels comparable to that of normal B cells. This finding indicates that ligation of CD40 on anergic B cells is a sufficiently strong signal to reactivate them and redirect them into the mature B cell pool that can differentiate to memory or immunoglobulin secreting plasma effector cells.

**Conclusion**

SLE is a complex, polygenic, chronic multisystem disease characterized by abnormal B cell activation and differentiation to plasma cells or plasmablasts/plasmacytes. Current research has begun to define the receptor–ligand interactions and signals that are involved in activation and differentiation of human B cells to plasma cells and plasmablasts/plasmacytes. Many of these genes are located within SLE susceptibility loci and their encoded molecules may be effective targets of biologic therapies in SLE patients. The exact cause of SLE is unclear but emergence of active disease may depend upon environmental factors that initiate and/or contribute to the development of this systemic autoimmune disease in genetically prone individuals. Notably, recent research has highlighted the central and active role that B cells play in regulating many aspects of the humoral immune response leading to differentiation of autoreactive effector B cell populations. Therefore, the possibility that ongoing B cell hyperreactivity in SLE, mediated by a number of defined receptor–ligand interactions, including signaling through CD40 or BAFF receptors, could be specifically targeted and should be considered as a novel approach to treat this systemic autoimmune disease.

**Competing interests**

None declared.

**References**

1. Grammer AC, Dorner T, Lipsky PE: Abnormalities in B cell activity and the immunoglobulin repertoire in human systemic lupus erythematosus. *Mol Pathol Autoimmune Dis* 2001, 2: 282-318.

2. Davidson A, Diamond B: Autoimmune diseases. *N Engl J Med* 2001, 345:340-350.

3. Lipsky PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. *Nat Immunol* 2001, 2:764-766.

4. Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. *Immunity* 2001, 15:397-408.

5. Grammer AC, Lipsky PE: CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. *Adv Immunol* 2000, 70:61-178.

6. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE: The CD40 ligand expressed by human B cells costimulates B cell responses. *J Immunol* 1995, 154:4966-5010.

7. Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE: Expression, regulation, and function of B cell-expressed CD154 in germinal centers. *J Immunol* 1999, 163:4150-4159.
8. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1509-1520.

9. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2003, 293:2111-2114.

10. Thiemann OT, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2003, 293:2108-2111.

11. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2003, 293:2108-2111.

12. von Bulow GU, van Deursen JM, Bram RJ: Cutting edge: a role for B lymphocyte stimulator in the normal development of B cells. J Immunol 2001, 167:341-352.

13. Moser KL, Neelas BR, Salmon JE, Yu H, Gray-Guerci C, Asundi N, Bruner GR, Fox J, Kelly J, Henshall S, Bacino D, Dietz M, Hogue R, Koelsch G, Nightingale L, Shaver T, Abdou NI, Albert DA, Carson C, Petri M, Treadwell EL, James JA, Harley JB: Germinal center formation in BAC-deficient mice: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA 1998, 95:14869-14874.

14. Cheema GS, Roschke V, Hibbert DM, Stohl W: Elevated serum levels of CD40L as a measure of T cell activation in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:1313-1319.

15. Zhang J, Roschke V, Baker WP, Wang Z, Alcorn GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2000, 165:666-670.

16. Donner T, Lipsky PE: Immunglobulin variable-region gene usage in systemic autoimmune diseases. Arthritis Rheum 2001, 44:2715-2727.

17. Grammer AC, McFarland RD, Heaney J, Damrell BF, Lipsky PE: Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol 1999, 163:4150-4159.

18. Yavuz S, Grammer AC, Yavuz AS, Nanki T, Lipsky PE: Comparative characteristics of mu chain and alpha chain transcripts expressed by individual tonsil plasma cells. Mol Immunol 2001, 38:19-34.

19. Calame KL: Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001, 2:1103-1108.

20. Ginsburg WW, Finkelman FD, Lipsky PE: Circulating and mitogen-induced immunoglobulin-secreting cells in human peripheral blood: evaluation by a modified reverse hemolytic plaque assay. J Immunol 1978, 120:33-39.

21. Jelink M, Lipsky PE: The role of B cell proliferation in the generation of immunoglobulin-secreting cells in man. J Immunol 1982, 128:3597-2604.

22. Vennio L, McAnally LM, Ramberg J, Lipsky PE: Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated anti-CD3-activated T cells. J Immunol 1992, 148:404-410.

23. McCarty GA, Rice JR, Bembo ML, Pisetsky DS: Independent expression of autoantibodies in systemic lupus erythematosus. J Rheumatol 1982, 9:691-695.

24. Perez MC, Wilson WA, Scopelitis E: Cyclophosphamide use in a young woman with antiphospholipid antibodies and recurrent cerebrovascular accident. South Med J 1989, 82:1421-1424.
47. Lettesjo H, Burd GP, Mageed RA: CD4+ T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB x NZW)F1 lupus-prone mice: phenotype and possible role in autoreactivity. J Immunol 2000, 165:4095-4104.

48. Poddar J, Weng X, Kay DG, Pare G, Calvo EL, Hanna Z, Kosco-Vilbois MH, Jolicoeur P: The AIDS disease of CD4C/HIV transgenic mice shows impaired germinal centers and autoantibodies and develops in the absence of IFN-gamma and IL-6. Immunity 2001, 15:173-185.

49. Higuchi T, Aiba Y, Nomura T, Matsuda J, Mochida K, Suzuki M, Kikutani H, Honjo T, Nishioka K, Tsubata T: Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 2002, 165:4095-4104.

50. Weyand CM, Kurtin PJ, Goronzy JJ: Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001, 159: 787-793.

51. van Nierop K, de Groot C: Human follicular dendritic cells; function, origin and development. Semin Immunol 2002, 14: 251-257.

52. de Boer BA, Voigt I, Kim HJ, Camacho SA, Lipp M, Forster R, Berek C: Affinity maturation in ectopic germinal centers. Curr Top Microbiol Immunol 2000, 251:191-195.

53. Fu YX, Storb U: Immunology. Autoreactive B cells migrate into T cell territory. Science 2002, 297:2006-2008.

54. Mandik-Nayak L, Bui A, Noorchashm H, Eaton A, Erikson J: Regulation of anti-double-stranded DNA B cells in nonautoimmune mice: localization to the T-B interface of splenic follicle. J Exp Med 1997, 188:1257-1267.

55. Wellmann U, Werner A, Winkler TH: Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA. Eur J Immunol 2001, 31:2800-2810.

56. Jacobson BA, Rothstein TL, Marshak-Rothstein A: Unique site of IgG2a and rheumatoid factor production in MRL/lpr mice. Immunol Rev 1997, 156:103-110.

57. Feuerstein N, Chen F, Madaio M, Eisenberg RA: Induction of autoimmunity in a transgenic model of B cell receptor peripheral tolerance: changes in coreceptors and B cell receptor-induced tyrosine-phosphoproteins. J Immunol 1999, 163:5287-5297.

58. Eris JM, Basten A, Brink R, Doherty K, Kehry MR, Hodgkin PD: Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA 1994, 91:4392-4396.

59. Cooke MP, Heath AW, Shokat KM, Zeng Y, Finkelman FD, Linsley PS, Howard M, Goodnow CC: Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 1994, 179:425-438.

Correspondence
Annie C Grammer, PhD, B cell Biology Group Leader, Autoimmunity Branch, NIAMS, NIH, 9000 Rockville Pike, Bldg. 10, Rm. 6D47A, Bethesda, MD 20892, USA. Tel: +1 301 594 3493; fax: +1 301 402 2209; e-mail: grammera@mail.nih.gov